{"id":79409,"date":"2026-09-08T12:39:03","date_gmt":"2026-09-08T04:39:03","guid":{"rendered":"https:\/\/flcube.com\/?p=79409"},"modified":"2026-09-08T12:39:04","modified_gmt":"2026-09-08T04:39:04","slug":"china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment","status":"publish","type":"post","link":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/","title":{"rendered":"China Medical System Licenses Leios Therapeutics&#8217; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Leios Therapeutics<\/strong>, an innovative <strong>aesthetic therapies company<\/strong>, announced on <strong>August 31, 2026<\/strong> that it has signed an <strong>exclusive licensing agreement<\/strong> with <strong>China Medical System Holdings Limited (CMS)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/0867:HKG\">HKG: 0867<\/a>) for <strong>10XB\u2011101<\/strong>, a proprietary <strong>injectable therapy containing polidocanol<\/strong>, alongside a related <strong>strategic equity investment<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure\" class=\"wp-block-heading\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Leios Therapeutics (innovative aesthetic therapies company)<\/td><\/tr><tr><td><strong>Licensee \/ Investor<\/strong><\/td><td>China Medical System Holdings Limited (CMS), HKG: 0867<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>10XB\u2011101 \u2014 proprietary injectable therapy containing polidocanol<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China: <strong>China including Hong Kong and Macau, excluding Taiwan<\/strong><\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive development, manufacturing, and commercialization<\/td><\/tr><tr><td><strong>Licensor Economics<\/strong><\/td><td><strong>Upfront payment + regulatory &amp; commercial milestone payments + royalties on future net sales<\/strong><\/td><\/tr><tr><td><strong>Parallel Transaction<\/strong><\/td><td>CMS to make a <strong>strategic equity investment<\/strong> in Leios<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>31 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Under the agreement, Leios will also <strong>support the advancement of the 10XB\u2011101 clinical development program<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Positioning:<\/strong> Best\u2011in\u2011class <strong>minimally invasive injectable treatment<\/strong> designed to <strong>reduce focal fat deposits<\/strong> and enhance <strong>body contouring outcomes<\/strong><\/li>\n\n\n\n<li><strong>Active Ingredient:<\/strong> <strong>Polidocanol<\/strong> \u2014 a <strong>synthetic non\u2011ionic detergent<\/strong> that induces <strong>targeted adipolysis<\/strong> (localized fat\u2011cell destruction)<\/li>\n\n\n\n<li><strong>Clinical Stage:<\/strong> <strong>Phase II clinical trials completed<\/strong> for the <strong>submental fat reduction<\/strong> indication (double\u2011chin fat)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Aesthetics Boom:<\/strong> Injectable, minimally invasive fat\u2011reduction products address fast\u2011growing demand in China&#8217;s medical aesthetics market, where surgical liposuction alternatives remain limited.<\/li>\n\n\n\n<li><strong>Best\u2011in\u2011Class Ambition:<\/strong> With Phase II trials already completed in submental fat reduction, 10XB\u2011101 enters the licensing stage with de\u2011risked clinical proof points ahead of pivotal China development.<\/li>\n\n\n\n<li><strong>Aligned Interests:<\/strong> The combination of <strong>milestone\u2011based economics, royalties, and an equity stake<\/strong> gives CMS upside in both the product and the company, while funding Leios&#8217; continued clinical program.<\/li>\n\n\n\n<li><strong>Portfolio Fit for CMS:<\/strong> The deal extends China Medical System&#8217;s footprint in <strong>aesthetic and consumer healthcare<\/strong> products beyond its established pharmaceutical base.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory approvals, milestone payments, and commercialization of 10XB\u2011101. Actual results may differ due to risks including trial outcomes, regulatory timelines, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[325,844,4934,100],"class_list":["post-79409","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-medical-system","tag-hkg-0867","tag-leios-therapeutics","tag-medical-aesthetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System Licenses Leios Therapeutics&#039; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Licenses Leios Therapeutics&#039; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment\" \/>\n<meta property=\"og:description\" content=\"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T04:39:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T04:39:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Licenses Leios Therapeutics&#8217; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment\",\"datePublished\":\"2026-09-08T04:39:03+00:00\",\"dateModified\":\"2026-09-08T04:39:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/\"},\"wordCount\":355,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"HKG: 0867\",\"Leios Therapeutics\",\"Medical aesthetics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/\",\"name\":\"China Medical System Licenses Leios Therapeutics' Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-08T04:39:03+00:00\",\"dateModified\":\"2026-09-08T04:39:04+00:00\",\"description\":\"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Licenses Leios Therapeutics&#8217; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/author\\\/wesley\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Licenses Leios Therapeutics' Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment - Insight, China&#039;s Pharmaceutical Industry","description":"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/","og_locale":"en_US","og_type":"article","og_title":"China Medical System Licenses Leios Therapeutics' Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment","og_description":"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.","og_url":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-08T04:39:03+00:00","article_modified_time":"2026-09-08T04:39:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/#article","isPartOf":{"@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Licenses Leios Therapeutics&#8217; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment","datePublished":"2026-09-08T04:39:03+00:00","dateModified":"2026-09-08T04:39:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/"},"wordCount":355,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","HKG: 0867","Leios Therapeutics","Medical aesthetics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/","url":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/","name":"China Medical System Licenses Leios Therapeutics' Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-08T04:39:03+00:00","dateModified":"2026-09-08T04:39:04+00:00","description":"Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB\u2011101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.","breadcrumb":{"@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Licenses Leios Therapeutics&#8217; Injectable Fat\u2011Reduction Therapy 10XB\u2011101 in Greater China, Alongside Strategic Equity Investment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/author\/wesley\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/comments?post=79409"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79409\/revisions"}],"predecessor-version":[{"id":79410,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79409\/revisions\/79410"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/media?parent=79409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/categories?post=79409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/tags?post=79409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}